alexa Searching Drugs For NF-κB Pathway Regulation: BIR1 Domains Of IAPs As Promising New Targets | 72458
ISSN: 0974-276X

Journal of Proteomics & Bioinformatics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

9th International Conference on Structural Biology

Luca Sorrentino
National Research Council, Italy
Posters & Accepted Abstracts: J Proteomics Bioinform
DOI: 10.4172/0974-276X-C1-101
Abstract
Inhibitor of apoptosis proteins are target of extensive research in the field of cancer therapy since they control apoptosis and cell survival. The most studied IAPs, namely XIAP, cIAP1 and cIAP2, were investigated for their ability to bind and inhibit caspases, thus blocking apoptosis. However, IAPs interaction network is much more complicated as they interact with multiple cellular partners to regulate the NF-kB signaling pathway, which is pivotal for cell survival. So far, the development of highly active Smac-mimetics (SM) targeting type II BIR domains of IAPs was pursued by many research groups. Nevertheless, in some cases, SM-mediated cIAP1 degradation leads to non-canonical NF-κB activation, by inducing cIAP2 gene expression, which overcomes cIAP1 absence and suppresses TNFα-mediated cell death. We propose to explore alternative mechanisms that can be exploited to interfere with IAP-involving signaling cascades in NF-κB regulation. We focused our attention on IAPs' type I BIR domains (BIR1), that lack the N-terminal peptide-binding groove necessary for SM-binding in type II BIR domains. The BIR1 domains of cIAP2 and of XIAP interact with a TRAF1:(TRAF2)2 heterotrimer and with TAB1, an upstream adaptor for TAK1 kinase activation, respectively, to regulate the canonical NF-κB signaling. We investigated the protein-protein interaction surfaces of IAPs' BIR1 domains finding that, in the crystal structures of cIAP2-BIR1/TRAFs and XIAP-BIR1/TAB1, they display an identical interaction surface. This observation points out remarkable common features in IAPs-BIR1 domains that can be exploited to identify a new class of molecules able to specifically inhibit type I BIR domains. In this context, we identified the compound NF023 and solved the crystal structures of human XIAP-BIR1 domain in the absence and presence of the inhibitor or of its analog cmp247. Furthermore, we identified several new molecules that could possibly inhibit XIAP-BIR1 homodimerization and that are currently under study.
Biography

Luca Sorrentino has always been interested in the study of proteins involved in the regulation of cell death or cell survival, two pivotal processes at the base of cancer development. During his education and PhD program, he gained expertise in cloning, production and purification of recombinant proteins followed by their thorough biochemical and structural characterization. Moreover, he also performed several experiments at the ESRF synchrotron in Grenoble. During the last years, he participated in international conferences and was supervisor of several graduate students. He is currently post-doc in the laboratory of Dr. Eloise Mastrangelo and Dr. Mario Milano (IBF-CNR, Milan, Italy), working on a project aimed at the structure-based design of a new class of compounds active in the regulation of the NF-κB pathway.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

generalsc[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7